Akebia Therapeutics, Inc.
Hedge Funds Holdings
Last updated:
Akebia Therapeutics, Inc.‘s stocks are currently a part of 65 hedge funds’ portfolios, which represents 25.28% of the total amount of its stocks outstanding. This makes up a total of 48.12M shares of Akebia Therapeutics, Inc.. Compared to the previous quarter, the number fell by -16.57% or -9.55M shares fewer. As for the holding position changes, 23.08% (15) of current hedge fund investors increased the number of shares held, 40% (26) of current holders sold a part of the shares held, and 24.62% (16) closed the holdings completely. 8 hedge funds are new holders of Akebia Therapeutics, Inc. stock in Q3 2022, it is 12.31% of total holders.
Hedge funds holding Akebia Therapeutics (Q4 2017 – Q3 2022)
| Q4 2017 | 128 |
|---|---|
| Q1 2018 | 151 |
| Q2 2018 | 142 |
| Q3 2018 | 128 |
| Q4 2018 | 161 |
| Q1 2019 | 163 |
| Q2 2019 | 145 |
| Q3 2019 | 144 |
| Q4 2019 | 147 |
| Q1 2020 | 151 |
| Q2 2020 | 184 |
| Q3 2020 | 153 |
| Q4 2020 | 136 |
| Q1 2021 | 138 |
| Q2 2021 | 133 |
| Q3 2021 | 119 |
| Q4 2021 | 126 |
| Q1 2022 | 115 |
| Q2 2022 | 83 |
| Q3 2022 | 65 |
Hedge funds changes in Akebia Therapeutics positions (Q4 2017 – Q3 2022)
| Q4 2017 | 29 | 52 | 33 | 19 | -5 |
|---|---|---|---|---|---|
| Q1 2018 | 44 | 48 | 37 | 18 | 4 |
| Q2 2018 | 20 | 57 | 37 | 29 | -1 |
| Q3 2018 | 19 | 42 | 42 | 33 | -8 |
| Q4 2018 | 49 | 73 | 24 | 15 | 0 |
| Q1 2019 | 26 | 47 | 51 | 24 | 15 |
| Q2 2019 | 22 | 58 | 28 | 36 | 1 |
| Q3 2019 | 19 | 46 | 43 | 20 | 16 |
| Q4 2019 | 23 | 50 | 45 | 18 | 11 |
| Q1 2020 | 27 | 53 | 42 | 22 | 7 |
| Q2 2020 | 46 | 77 | 42 | 14 | 5 |
| Q3 2020 | 27 | 68 | 41 | 56 | -39 |
| Q4 2020 | 16 | 45 | 52 | 32 | -9 |
| Q1 2021 | 20 | 48 | 45 | 17 | 8 |
| Q2 2021 | 16 | 53 | 38 | 20 | 6 |
| Q3 2021 | 8 | 49 | 34 | 22 | 6 |
| Q4 2021 | 25 | 43 | 35 | 18 | 5 |
| Q1 2022 | 17 | 39 | 43 | 28 | -12 |
| Q2 2022 | 23 | 16 | 32 | 52 | -40 |
| Q3 2022 | 8 | 15 | 26 | 16 | 0 |
Hedge funds changes in Akebia Therapeutics stock options (Q4 2017 – Q3 2022)
| Q4 2017 | 391,000 | 185,000 |
|---|---|---|
| Q1 2018 | 3,241,000 | 224,000 |
| Q2 2018 | 8,997,000 | 662,000 |
| Q3 2018 | 8,215,000 | 810,000 |
| Q4 2018 | 4,157,000 | 1,312,000 |
| Q1 2019 | 3,233,000 | 1,524,000 |
| Q2 2019 | 24,383,000 | 695,000 |
| Q3 2019 | 19,297,000 | 468,000 |
| Q4 2019 | 4,355,000 | 1,455,000 |
| Q1 2020 | 10,885,000 | 1,403,000 |
| Q2 2020 | 26,091,000 | 3,016,000 |
| Q3 2020 | 5,323,000 | 2,154,000 |
| Q4 2020 | 6,418,000 | 2,350,000 |
| Q1 2021 | 2,136,000 | 3,566,000 |
| Q2 2021 | 2,303,000 | 3,770,000 |
| Q3 2021 | 1,518,000 | 1,798,000 |
| Q4 2021 | 5,204,000 | 674,000 |
| Q1 2022 | 4,348,000 | 2,636,000 |
| Q2 2022 | 212,000 | 65,000 |
| Q3 2022 | 282,000 | 47,000 |